참고문헌
- Burkhart, C. A., Berman, J. W., Swindell, C. S., and Horwitz, S. B., Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-a gene expression and cytotoxicity. Cancer Res., 54, 5779-5782 (1994)
- Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., and Winer, E. P. Docetaxel administered on a weekly basis for metastatic breast cancer. J. Clin. Oncol., 18, 1212-1219 (2000) https://doi.org/10.1200/JCO.2000.18.6.1212
- Carlson, R. W., Quality of life issues in the treatment of metastatic breast cancer. Oncology, 12, 27-31 (1998)
- Carmichael, J., Jones, A., and Hutchinson, T., A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. Semin. Oncol., 24, 44-47 (1997)
- Chang, A. Y., Boros, L., Asbury, R., Hui, L., and Rubins, J., Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin. Oncol., 24, 17-71 (1997)
- Cortes, J. E., Pazdur, and R., Docetaxel. J. Clin. Oncol., 13, 2643- 2655 (1995) https://doi.org/10.1200/JCO.1995.13.10.2643
- Esteva, F. J., Valero, V., Pusztai, L., Boehnke, L.,-M., Buzdar, A. U., and Hortobagyi,G. N., Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. The Oncologist, 6, 133-146 (2001) https://doi.org/10.1634/theoncologist.6-2-133
- Greenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., and Buzdar, A. U., Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol., 14, 2197-2205 (1996) https://doi.org/10.1200/JCO.1996.14.8.2197
- Hainsworth, J. D., Burris, H. A., Erland, J. B., Thomas, M., and Greco, F. A., Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol., 16, 2164-2168 (1998) https://doi.org/10.1200/JCO.1998.16.6.2164
- Hainsworth, J. D., Burris, H. A., and Greco, F. A., Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin. Oncol., 26, 19-24 (1999)
- Hansen, M. B., Nielsen, S. E., and Berg, K., Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods, 119, 203-210 (1989) https://doi.org/10.1016/0022-1759(89)90397-9
- Jassem, J., Pienkowski, T., Pluzanska, A., Jelic, S., Gorbunova, V., Mrsic, Z., -K., Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., Munier, S., and Weil, C., Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J. Clin. Oncol., 19, 1707-1715 (2001) https://doi.org/10.1200/JCO.2001.19.6.1707
- Klaassen, U., Wilke, H., Strumberg, D., Eberhardt, W., Korn, M., and Seeber, S., Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur. J. Cancer, 32, 547-549(1996) https://doi.org/10.1016/0959-8049(95)00641-9
- Lembersky, B. C., Anderson, S., Smith, R., Brown, A., Nesbitt, L., Aikin, J., Fehrenbacher, L., Jochimsen, P., Thirlwell, M. P., and Mamounas, E.P., Phase II trial of doxorubicin and docetaxel for locally advanced and metastatic breast cancer: preliminary results from NSABP BP-57. Proc. Am. Soc. Clin. Oncol., 19, 403 (2000)
- Mullins, D. W., Walker, T. M., Burger, C. J. and Elgert, K. D., Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities. Cancer. Immunol. Immunother., 45, 20-28 (1997) https://doi.org/10.1007/s002620050396
- Nabholtz, J. M., Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin. Oncol., 26, 7-13 (1999)
- Nabholtz, J. M., Tonkin, K., Smylie, M., Au, H. J., Lindsay, M. A., and Mackey, J., Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Exp. Opin. Pharmacother., 1, 187-206 (2000) https://doi.org/10.1517/14656566.1.2.187
- Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J. G., Gamucci, T., Houston, S., Coleman, R., Schachter, J., Vreckem, A., Sylvester, R., Awada, A., Wildiers, J., and Piccart, M., Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol., 18, 724-733 (2000) https://doi.org/10.1200/JCO.2000.18.4.724
- Pazdur, R., Kudelka, A.P., Kavanagh, J.J., Cohen, P.R., and Raber, M.N., The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer. Treat. Rev., 19, 351-386 (1993) https://doi.org/10.1016/0305-7372(93)90010-O
- Perez, E.A., Current management of metastatic breast cancer. Semin. Oncol, 26, 1-10 (1999)
- Rowinsky, E. K., The taxanes: dosing and scheduling considerations. Oncology, 11, 7-19 (1997)
- Seidman, A. D., Hudis, C. A., Albanel, J., Tong, W., Tepler, I., Currie, V., Moynahan, M. E., Theodoulou, M., Gollub, M., Baselga, J., and Norton, L., Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16, 3353-3361 (1998) https://doi.org/10.1200/JCO.1998.16.10.3353
- Stemmler, H. J., Gutschow, K., Sommer, H., Malekmohammadi, M., Kentenich, C. H., Forstpointner, R, Geuenich, S., Bischoff, J., Hiddemann, W., and Heinemann, V., Weekly docetaxel (Taxotereo) in patients with metastatic breast cancer. Ann. Oncol., 12, 1393-1398 (2001) https://doi.org/10.1023/A:1012557528952
- Valero, V., Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin. Oncol., 24, 13-18 (1997)
- Von Hoff, D. D.,The taxoids: same roots, different drugs. Semin. Oncol., 24, 3-13(1997)
- Warburton, S., and James, R., Haemocytometer cell counts and viability studies. In: Doyle, A., Grifits, J. B., and Newell D. G. (eds.), Cell and tissue culture laboratory procedures, Chichester, John Wiley, pp. 411-415 (1994)
- White, C. M., Martin, B. K., Lee, L. F., Haskill, J. S., and Ting, J.P., Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer. Immunol. Immunother., 46, 104-112 (1998) https://doi.org/10.1007/s002620050468